<?xml version="1.0" encoding="UTF-8"?>
<p id="p0630">In spite of a great effort worldwide, current drugs have only a limited efficacy in treating COVID-19; on the other hand, given the high rate of infectivity of SARS-CoV-2 with diffuse lethal effects, especially in immunocompromised patients, the design of new drugs targeting specific activities of the virus and its infection cycle is essential 
 <xref rid="b0875" ref-type="bibr">[175]</xref>.
</p>
